Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

11,329 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-World, Long-Term Outcomes of Nivolumab Therapy for Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck and Impact of the Magnitude of Best Overall Response: A Retrospective Multicenter Study of 88 Patients.
Matsuki T, Okamoto I, Fushimi C, Takahashi H, Okada T, Kondo T, Sato H, Ito T, Tokashiki K, Tsukahara K, Hanyu K, Masubuchi T, Tada Y, Miura K, Omura G, Sawabe M, Kawakita D, Yamashita T. Matsuki T, et al. Among authors: ito t. Cancers (Basel). 2020 Nov 18;12(11):3427. doi: 10.3390/cancers12113427. Cancers (Basel). 2020. PMID: 33218183 Free PMC article.
Predicting the efficacy of chemoradiotherapy for locally advanced human papilloma virus-related oropharyngeal squamous cell carcinoma using one course of TPF chemotherapy.
Kondo T, Tsukahara K, Okamoto I, Sato H, Okada T, Maruyama R, Hihara K, Ito T, Takeda A, Kikawada N, Aihara Y, Ogawa Y. Kondo T, et al. Among authors: ito t. Eur Arch Otorhinolaryngol. 2021 Sep;278(9):3497-3506. doi: 10.1007/s00405-020-06549-9. Epub 2021 Jan 2. Eur Arch Otorhinolaryngol. 2021. PMID: 33386967
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
Okada T, Fushimi C, Matsuki T, Okamoto I, Sato H, Kondo T, Tokashiki K, Kishida T, Ito T, Yamashita G, Aihara Y, Hanyu K, Kushihashi Y, Masubuchi T, Tada Y, Miura K, Harada Y, Momiyama K, Yamashita T, Omura GO, Takahashi H, Oridate N, Tsukahara K. Okada T, et al. Among authors: ito t. Anticancer Res. 2022 Mar;42(3):1607-1613. doi: 10.21873/anticanres.15635. Anticancer Res. 2022. PMID: 35220258
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
Okada T, Fushimi C, Matsuki T, Tokashiki K, Takahashi H, Okamoto I, Sato H, Kondo T, Hanyu K, Kishida T, Ito T, Yamashita G, Masubuchi T, Tada Y, Miura K, Omura GO, Yamashita T, Oridate N, Tsukahara K. Okada T, et al. Among authors: ito t. Anticancer Res. 2023 Jun;43(6):2717-2724. doi: 10.21873/anticanres.16438. Anticancer Res. 2023. PMID: 37247908
11,329 results
You have reached the last available page of results. Please see the User Guide for more information.